^
Association details:
| Biomarker: | EGFR mutation + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
Excerpt:
Of the 42 patients with advanced NSCLC harboring EGFR mutations who received TKIs….The mutations predictive of poor survival in our cohort were found in PIK3CA, PTEN, KRAS and SMAD4.
DOI:
10.21873/cgp.20216
